We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipelin... Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. Show more
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLβ’ siRNA gene silencing technology...
MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLβ’ siRNA gene silencing technology...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.8 | -18.3908045977 | 4.35 | 4.99 | 3.3502 | 185415 | 3.79558921 | CS |
4 | 2.8697 | 421.828605027 | 0.6803 | 6.18 | 0.57 | 88624 | 3.25917524 | CS |
12 | 2.74 | 338.271604938 | 0.81 | 6.18 | 0.57 | 78940 | 1.70413077 | CS |
26 | 2.95 | 491.666666667 | 0.6 | 6.18 | 0.5 | 263027 | 0.95252093 | CS |
52 | 0.77 | 27.6978417266 | 2.78 | 6.18 | 0.5 | 522992 | 1.81754073 | CS |
156 | -18.77 | -84.0949820789 | 22.32 | 29.04 | 0.5 | 652386 | 14.07645027 | CS |
260 | -1.364 | -27.7574277574 | 4.914 | 130.2 | 0.5 | 721810 | 19.11470438 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions